Aylward, Mansel, Maddock, Jeffrey, Lewis, Peter A. and Rees, Philip L. 1977. Oestrogen replacement therapy and blood clotting. Current Medical Research and Opinion 4 (supp 3) , pp. 83-100. 10.1185/03007997709109388 |
Abstract
A double-blind between-patient comparative trial was carried out over 6 months in 60 menopausal women with piperazine oestrone sulphate (3 mg/day), ethinyl oestradiol (30 μg/day), and placebo. This was followed by 18 months' observation during which all patients received piperazine oestrone sulphate. Biochemical and metabolic investigations and tests of blood clotting and platelet function were carried out at monthly intervals. The results suggest that piperazine oestrone sulphate did not produce any adverse effects on blood coagulation, either during the initial 6-month trial or during the follow-up period. Treatment with ethinyl oestradiol, however, produced pronounced changes in prothrombin time and Factor VII assays, whilst Factor X, cephalin time and platelet aggregation times were all adversely affected. Moreover, these changes in clotting factors produced by ethinyl oestradiol persisted for periods of up to 9 months after the oestrogen was discontinued and piperazine oestrone sulphate was substituted. The authors comment that the data lend considerable support to the proposal that certain ‘natural’ oestrogens may not provoke adverse changes in blood clotting and platelet function.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Subjects: | R Medicine > R Medicine (General) R Medicine > RG Gynecology and obstetrics R Medicine > RM Therapeutics. Pharmacology |
Uncontrolled Keywords: | piperazine oestrone sulphate, ethinyl oestradiol, menopause, blood coagulation, platelet adhesiveness |
Publisher: | Informa Healthcare |
ISSN: | 0300-7995 |
Last Modified: | 04 Jun 2017 04:18 |
URI: | https://orca.cardiff.ac.uk/id/eprint/36547 |
Citation Data
Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |